Aura Biosciences
Aura Biosciences is a United States-based biotechnology company running 2 late-stage cancer trials of AU-011 in melanoma and uveal melanoma.
Overview
Aura Biosciences, based in Boston, MA, the United States, is a biotechnology company. Aura Biosciences is a clinical-stage biotechnology company developing targeted oncology therapies for ocular cancers using its proprietary Virus-Like Drug Conjugate (VDC) technology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing AU-011 in melanoma and uveal melanoma. The largest, NCT06007690 (A Phase 3 Randomised, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma), plans to enrol 108 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyiOnctura
Shares Uveal melanoma, Melanoma and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Uveal melanoma, Melanoma and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Melanoma and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Melanoma and the tag ctgov-sponsor.
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.